RPRX logo

Royalty Pharma (RPRX) Stock

Profile

Full Name:

Royalty Pharma plc

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

16 June 2020

Indexes:

Not included

Description:

Royalty Pharma (RPRX) is a company that invests in pharmaceutical royalties. It buys rights to future sales of drugs from developers, allowing them to receive upfront cash. In return, Royalty Pharma earns money as the drugs generate sales, helping to fund new treatments and innovations in healthcare.

Key Details

Price

$31.22

TTM Dividend Yield

2.69%(-4.61% YoY)

Annual Revenue

$2.35 B(+5.24% YoY)

Annual EPS

$2.53(+2430.00% YoY)

PE Ratio

12.24(+8.61% YoY)

Beta

-0.01

Events Calendar

Earnings

Next earnings date:

Feb 14, 2025

Recent quarterly earnings:

Nov 06, 2024

Recent annual earnings:

Feb 15, 2024
Dividend

Next ex-dividend date:

Feb 21, 2025

Recent ex-dividend date:

Nov 15, 2024
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

25 Oct '24 Citigroup
Buy
14 Aug '24 Goldman Sachs
Buy
11 July '24 Morgan Stanley
Overweight
03 June '24 UBS
Neutral
12 Apr '24 B of A Securities
Buy
20 Feb '24 JP Morgan
Overweight
20 Feb '24 Goldman Sachs
Buy
09 Nov '23 Morgan Stanley
Overweight
11 Oct '23 Morgan Stanley
Overweight
09 Aug '23 Morgan Stanley
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
Royalty Pharma to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025
RPRX
globenewswire.com28 January 2025

On January 28, 2025, Royalty Pharma plc (Nasdaq: RPRX) announced that it will share its financial results for the fourth quarter and the entire year of 2024 on February 11, 2025, before the U.S. markets open. The company will also hold a conference call and a live webcast at 8:30 a.m. Eastern Time on that day.

Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know
Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know
Wall Street Analysts Predict a 31.15% Upside in Royalty Pharma (RPRX): Here's What You Should Know
RPRX
zacks.com20 January 2025

Analysts' average price targets for Royalty Pharma (RPRX) suggest that the stock could increase by 31.2%. Although this popular measure hasn't always been very reliable, the consensus among analysts to raise earnings estimates does suggest potential growth for the stock.

Royalty Pharma: Key Strategic Updates To Be Priced In
Royalty Pharma: Key Strategic Updates To Be Priced In
Royalty Pharma: Key Strategic Updates To Be Priced In
RPRX
seekingalpha.com15 January 2025

Important strategic changes involve the purchase of RP Management LLC, streamlining the company structure, cutting costs, and improving shareholder alignment. A new $3 billion share buyback plan and a 5% increase in dividends show effective use of capital while keeping financial flexibility and a good credit rating. The company's valuation looks attractive, with a potential 30% increase, and expected savings and buybacks indicate further growth in earnings per share, supporting our positive outlook.

Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors
Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors
Royalty Pharma (RPRX) Crossed Above the 200-Day Moving Average: What That Means for Investors
RPRX
zacks.com13 January 2025

From a technical viewpoint, Royalty Pharma (RPRX) appears to be an appealing choice since it has hit an important support level. The stock recently moved above the 200-day moving average, indicating a positive long-term trend.

Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher?
Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher?
Did Royalty Pharma (RPRX) Close Shortened Trading Week Higher?
RPRX
Insider Monkey11 January 2025

We have just released a list of 10 companies that performed well during a shortened trading week. In this article, we will examine how Royalty Pharma plc (NASDAQ:RPRX) compares to these other companies. On Friday, Wall Street's major indices finished the shortened trading week lower after labor-related news.

Royalty Pharma simplifies corporate structure with $1.1 bln deal
Royalty Pharma simplifies corporate structure with $1.1 bln deal
Royalty Pharma simplifies corporate structure with $1.1 bln deal
RPRX
reuters.com10 January 2025

On Friday, Royalty Pharma announced that it plans to spend around $1.1 billion to buy RP Management, a company that oversees its operations. This move is part of the healthcare firm's effort to make its corporate structure simpler.

Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
Royalty Pharma Announces Transformative Step in Company's Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program
RPRX
globenewswire.com10 January 2025

Royalty Pharma plc plans to become a fully integrated company by purchasing its external manager, RP Management, LLC. This move is expected to save over $100 million annually by 2026, increasing to more than $175 million by 2030, with total savings exceeding $1.6 billion over ten years. Additionally, the company has approved a $3 billion share buyback program, with $2 billion set to be repurchased in 2025, depending on market conditions.

Royalty Pharma Announces Dividend Increase
Royalty Pharma Announces Dividend Increase
Royalty Pharma Announces Dividend Increase
RPRX
globenewswire.com09 January 2025

On January 9, 2025, Royalty Pharma plc (Nasdaq: RPRX) announced that its board of directors has approved a dividend of $0.22 for the first quarter of 2025 for each Class A ordinary share. This marks a 5% rise in the quarterly dividend compared to the previous quarter.

2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips
2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips
RPRX
fool.com04 December 2024

The main stock indexes continue to rise, but there are still some lesser-known stocks that are worth considering. Some of these overlooked companies provide good dividend yields and consistent growth in their payouts, even if their stock prices don't reflect this.

Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma to Present at Upcoming Investor Conferences
RPRX
globenewswire.com27 November 2024

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) has announced its participation in several investor conferences scheduled for December.

FAQ

  • What is the primary business of Royalty Pharma?
  • What is the ticker symbol for Royalty Pharma?
  • Does Royalty Pharma pay dividends?
  • What sector is Royalty Pharma in?
  • What industry is Royalty Pharma in?
  • What country is Royalty Pharma based in?
  • When did Royalty Pharma go public?
  • Is Royalty Pharma in the S&P 500?
  • Is Royalty Pharma in the NASDAQ 100?
  • Is Royalty Pharma in the Dow Jones?
  • When was Royalty Pharma's last earnings report?
  • When does Royalty Pharma report earnings?
  • Should I buy Royalty Pharma stock now?

What is the primary business of Royalty Pharma?

Royalty Pharma (RPRX) is a company that invests in pharmaceutical royalties. It buys rights to future sales of drugs from developers, allowing them to receive upfront cash. In return, Royalty Pharma earns money as the drugs generate sales, helping to fund new treatments and innovations in healthcare.

What is the ticker symbol for Royalty Pharma?

The ticker symbol for Royalty Pharma is NASDAQ:RPRX

Does Royalty Pharma pay dividends?

Yes, Royalty Pharma pays dividends. The last payment was $0.21, with an ex-dividend date on 15 November 2024

What sector is Royalty Pharma in?

Royalty Pharma is in the Healthcare sector

What industry is Royalty Pharma in?

Royalty Pharma is in the Biotechnology industry

What country is Royalty Pharma based in?

Royalty Pharma is headquartered in United States

When did Royalty Pharma go public?

Royalty Pharma's initial public offering (IPO) was on 16 June 2020

Is Royalty Pharma in the S&P 500?

No, Royalty Pharma is not included in the S&P 500 index

Is Royalty Pharma in the NASDAQ 100?

No, Royalty Pharma is not included in the NASDAQ 100 index

Is Royalty Pharma in the Dow Jones?

No, Royalty Pharma is not included in the Dow Jones index

When was Royalty Pharma's last earnings report?

Royalty Pharma's most recent earnings report was on 6 November 2024

When does Royalty Pharma report earnings?

The next expected earnings date for Royalty Pharma is 14 February 2025

Should I buy Royalty Pharma stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions